What Is Whole-Brain c-Fos Mapping?

What does c-Fos measure, and what doesn't it measure?

c-Fos is a marker of recent neuronal activation. When a neuron fires strongly enough, the c-fos gene is transcribed rapidly, and the protein becomes detectable within about 30 to 60 minutes, peaks at roughly 60 to 120 minutes and returns toward baseline within a few hours. Fixing the brain inside that window captures a snapshot of which cells responded to whatever happened shortly before.

That snapshot has clear limits, and they shape how a study should be designed:

• It is one time window, not a recording. c-Fos reflects activation in the hour or two before tissue collection, not sustained activity over days.
• It does not directly report inhibition. A region that is suppressed by a drug will not light up, and an increase in c-Fos does not by itself say whether the activated cells are excitatory or inhibitory.
• Not every activated cell reaches a detectable level. Sensitivity varies between cell types, so a negative region is not proof that the region was uninvolved. It can also mean the timing window missed the response.

Timing is the variable that matters most. For a drug study, the right moment to collect brains depends on the compound's pharmacokinetics: collect too early and the c-Fos response has not built up, collect too late and it has already faded. As Jacob Hecksher-Sørensen, CEO and co-founder of Vibraint, put it in our product series:

"Because it is a marker that goes up and then disappears, you don't want to wait too long, and you don't want to look too early. So there's a little bit of discussion in how you design your study, and I would always recommend that we do that first."

Fos vs. c-Fos: Fos refers to the protein family. c-Fos is specifically the product of the c-fos immediate early gene, and it is the member most widely used to visualize recent neuronal activation because it is induced quickly and reliably across most neuron types.

How whole-brain c-Fos mapping works: the four-step pipeline

The general technique has four stages. Each one can be run on its own or combined into a single end-to-end study.

1. Whole-brain immunolabeling and tissue clearing

The intact brain is stained with an anti-c-Fos antibody and made optically transparent, most commonly with the iDISCO+ protocol. This is the slowest step, and its duration does not depend much on study size, because antibodies need time to penetrate the whole tissue evenly. In Jacob's words: "Whether you have one brain or a hundred brains, it will take a month, just to allow the antibodies to penetrate into the tissue and have uniform, nice labeling." Learn more about whole-brain immunolabeling.

2. Light sheet microscopy

The cleared brain is imaged in 3D with a light sheet microscope at cellular resolution. Scanning one brain takes roughly one to two hours depending on the number of labels, and produces around 1 TB of raw data. Unlike the immunolabeling step, imaging time scales linearly with the number of brains. See the light sheet imaging step.

3. AI-assisted image analysis and atlas registration

Individual c-Fos-positive cells are detected automatically, and each brain is registered to a 3D reference atlas so every cell can be assigned to an anatomical region. This is where most of the practical difficulty lies: datasets of this size are hard to move, store and process, which is why analysis is often the bottleneck for labs that already own a light sheet microscope.

Atlas choice matters for accuracy. The Perens light sheet reference atlas was built from 139 iDISCO+ brains imaged with light sheet microscopy, so it matches the shape of cleared tissue. In the original publication, registering semaglutide-induced c-Fos data to the standard Allen CCFv3 instead assigned part of the hindbrain signal to the dorsal motor nucleus of the vagus (DMX) rather than the nucleus of the solitary tract (NTS) (Perens et al. 2021, Neuroinformatics). Read about AI-assisted image analysis.

4. Study report (optional)

For many projects the quantitative data and 3D maps are the deliverable. When a formal study report is needed, for example for an internal decision or a regulatory package, it is written after the data has been reviewed, so the report can focus on the regions that turned out to matter.

At Vibraint, these four stages make up LS-Journey™. A typical full-pipeline study takes around two to two and a half months from the day brains arrive in our lab to the day the data is live on CNS-Voyager™, with about one month of that spent on immunolabeling. Brains are QC-checked on arrival, and each move to a new step (lab processing, microscopy, analysis, upload) is communicated as it happens. Labs that already have their own light sheet data can use the analysis module on its own.

c-Fos mapping vs. fMRI: what's the difference?

Whole-brain c-Fos mapping and fMRI both describe brain activity, but they measure different things at very different scales. They are better thought of as complementary than as competing methods.

If the question is "which cells, in which nuclei, responded to this compound?", c-Fos gives the more precise answer. If the question is "how does activity change over time in the same individual?", fMRI is the method that can follow it. A natural next step for translational programs is to use both: whole-brain c-Fos in mice to identify the responding circuits at cellular resolution, and imaging in larger species or humans to test whether the same regions respond.

What is whole-brain c-Fos mapping used for?

Because no regions need to be selected in advance, the method is most useful when the answer may sit somewhere unexpected.

• Obesity and GLP-1 drug research. Whole-brain c-Fos mapping of six classes of weight-lowering drugs, including semaglutide and setmelanotide, across 308 brain regions showed that all six activated an overlapping set of feeding centers in the dorsal vagal complex and hypothalamus, while each class also left its own signature elsewhere (Hansen, Perens et al. 2021, Molecular Metabolism; Johanna Perens, now Vibraint's CTO, shares first authorship and ran the study as part of her PhD). Read more about how semaglutide affects the brain.
• CNS drug mechanism of action. Where a drug goes and where the brain responds are not always the same place. In liraglutide-treated mice, most c-Fos activation appeared in regions the drug did not reach directly, pointing to secondary activation through a parabrachial pathway (Salinas et al. 2018, Scientific Reports). Pairing activity maps with whole-brain biodistribution data separates direct from downstream effects.
• Genetic models and phenotyping. Comparing knockout and wild-type animals shows how removing a gene changes the brain's response to a stimulus or behavior.
• Behavior, stress and reward circuits. Mapping the response to a behavioral paradigm across all regions at once, instead of testing one hypothesis per experiment.
• Neurodegeneration research. Following how disease models alter activation patterns across the brain.

Whole-brain imaging data has also carried regulatory weight before. Whole-brain biodistribution mapping by Vibraint's founders at Novo Nordisk supported the NDA for Saxenda (liraglutide), the first FDA-approved peptide-based obesity drug.

For audience-specific detail, see c-Fos in preclinical drug discovery and whole-brain c-Fos for discovering new biology.

Why whole-brain data belongs in an interactive viewer

A single c-Fos brain contains cell counts for 800+ regions, plus the 3D position of every detected cell. A static report can show only a fraction of that. Jacob described the limitation of the old delivery format directly:

"Previously we've been making reports and PowerPoint presentations, but it always limits you to look at maybe 10 or 20 brain regions, and maybe you didn't look at exactly the right section. Here, because you can scroll through the brain in any dimension you want, you can look up any brain region you want."

This is why LS-Journey™ data is delivered on CNS-Voyager™ rather than as a file transfer. In the viewer you can open, for example, the arcuate nucleus of the hypothalamus, see the number of c-Fos-positive cells per animal in that region, and link those counts to the exact 3D positions of the cells. Data stays private to your study, collaborators can be invited into the same protected workspace, and figures, images, movies and plots can be exported for publications or reports.

Your own maps can also be viewed alongside public datasets in the same atlas space, including Allen Brain connectivity, spatial transcriptomics, whole-genome ABC Atlas gene expression maps and published c-Fos datasets. Combining activity with connectivity and gene expression in one coordinate system is what we call integrative spatial biology.

How to explore c-Fos mapping data yourself

CNS-Voyager™ is built on the same peer-reviewed Perens CCF reference brain described above, and it is open to any neuroscientist by subscription, with a reduced tier for PhD students. It is a direct way to see what whole-brain c-Fos data looks like before designing a study. Browse c-Fos data on CNS-Voyager™.

Frequently asked questions

What is whole-brain c-Fos mapping?

Whole-brain c-Fos mapping detects and counts c-Fos-positive neurons across the entire mouse brain at once, using whole-brain immunolabeling, light sheet microscopy and registration to a brain atlas. Because c-Fos is an immediate early gene expressed after neuronal activation, it reveals which of 800+ annotated brain regions were active after a stimulus, behavior or drug treatment, without selecting regions of interest in advance.

How long does c-Fos expression last after a stimulus?

c-Fos protein typically becomes detectable within 30 to 60 minutes of neuronal activation, peaks around 60 to 120 minutes and returns to baseline within a few hours. This narrow window is why the timing of tissue collection relative to the stimulus is one of the most important variables in a c-Fos study.

What is the difference between Fos and c-Fos?

Fos is the protein family. c-Fos specifically refers to the protein product of the c-fos immediate early gene, which is the marker most commonly used to visualize recent neuronal activation because it is induced rapidly and reliably across most neuron types.

How does whole-brain c-Fos mapping compare to fMRI?

Whole-brain c-Fos mapping gives single-cell resolution across the entire mouse brain but requires terminal tissue collection at one time point. fMRI measures blood-oxygen-level-dependent signal in real time and can be repeated in the same living subject, at much coarser spatial resolution. The two techniques are complementary.

What is c-Fos a marker for?

c-Fos is a marker of recent neuronal activation. Its presence indicates that a neuron was strongly activated and transcribed the c-fos gene within roughly the prior one to two hours. It does not directly indicate inhibition, sustained activity outside that window, or activation in every cell type at equal sensitivity.

How long does a whole-brain c-Fos study take?

A full-pipeline study typically takes around two to two and a half months from sample receipt to data delivery. About one month is needed for whole-brain immunolabeling regardless of the number of brains, because antibodies need time to penetrate the intact tissue evenly. Imaging takes roughly one to two hours per brain, followed by automated analysis and atlas registration.

Plan a whole-brain c-Fos study

Study design, especially the timing of tissue collection, decides what a c-Fos map can show. We work with academic, biotech and pharma teams in Europe, the US, the UK and Australia, and we start every c-Fos study with a design discussion. Explore LS-Journey™ or explore the data live on CNS-Voyager™.

References

1. Perens J, Salinas CG, Skytte JL, et al. An optimized mouse brain atlas for automated mapping and quantification of neuronal activity using iDISCO+ and light sheet fluorescence microscopy. Neuroinformatics 2021;19:433-446. doi:10.1007/s12021-020-09490-8
2. Hansen HH, Perens J, Roostalu U, et al. Whole-brain activation signatures of weight-lowering drugs. Molecular Metabolism 2021;47:101171. doi:10.1016/j.molmet.2021.101171
3. Salinas CBG, Lu TT, Gabery S, et al. Integrated brain atlas for unbiased mapping of nervous system effects following liraglutide treatment. Scientific Reports 2018;8:10310. doi:10.1038/s41598-018-28496-6